论文部分内容阅读
目的:观察还原型谷胱甘肽联合甘利欣治疗酒精性肝病的临床疗效。方法:回顾性分析我院2009年2月—2010年7月收治的102例酒精性肝病患者的临床资料,常规治疗的50例作为对照组,还原型谷胱甘肽联合甘利欣治疗的52例作为观察组,对两组的疗效及不良反应情况进行比较分析。结果:观察组的总有效率为94.2%,明显高于对照组的80.0%,组间差异有统计学意义(P<0.05);两组不良反应发生率分别为3.8%、4.0%,组间差异无统计学意义(P>0.05),且不良反应症状均较轻微,能够自行缓解。结论:还原型谷胱甘肽联合甘利欣治疗酒精性肝病疗效满意,能够明显提高总有效率,且安全性好,值得临床推广应用。
Objective: To observe the clinical efficacy of reduced glutathione and Glycyrrhizin in the treatment of alcoholic liver disease. Methods: The clinical data of 102 patients with alcoholic liver disease admitted in our hospital from February 2009 to July 2010 were retrospectively analyzed. Fifty patients in the routine treatment group were treated as control group and 52 patients treated with reduced glutathione combined with glycyrrhizin As the observation group, the two groups of efficacy and adverse reactions were compared. Results: The total effective rate in the observation group was 94.2%, which was significantly higher than that in the control group (80.0%, P <0.05). The incidence of adverse reactions in the two groups were 3.8% and 4.0% The difference was not statistically significant (P> 0.05), and the adverse reaction symptoms were mild, able to ease themselves. Conclusion: The reduced glutathione combined with Gan Lixin treatment of alcoholic liver disease with satisfactory results, can significantly improve the total effective rate, and the safety is good, worthy of clinical promotion and application.